Preliminary findings of a phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma

Category Primary study
JournalNeuro-Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 45072814d059981b33bc0ed702bd2a43e06fd17b
First added on: Feb 11, 2025